Subject: DaunoXome May Be Able To Treat Kaposi's Sarcoma
Date: Published: 12/11/91 (34 lines)
Source:  Wall Street Journal.  Copyright Dow Jones & Co. Inc. 

    Business Brief -- Vestar Inc.:
    DaunoXome May Be Able
    To Treat Kaposi's Sarcoma

    Vestar Inc. said clinical results reported at a medical
 meeting indicate that its drug DaunoXome may have
 "significant capability" as a treatment for AIDS-related
 Kaposi's sarcoma.
    DaunoXome is a formulation of daunorubicin, an established
 cancer drug that previously wasn't used in AIDs patients.
    Vestar, based in San Dimas, Calif., reported to the
 American Society of Hematology annual meeting that 60% of 16
 AIDS patients with Kaposi's sarcoma showed a reduction in the
 number, growth or size of lesions.  And 40% showed a
 stabilization of the cancer, Vestar said.  DaunoXome can be
 used safely with AIDS patients who are also taking AZT,
 currently the principal treatment for AIDS patients, it
 reported.
    Kaposi's sarcoma is characterized by lesions of the skin,
 mucous membranes, lymph nodes and internal organs.  It affects
 an estimated 15% or more of AIDS patients.  Vestar develops,
 tests, manufactures and markets pharmaceuticals to treat
 patients with cancer and serious infections, including AIDS.  
 The company said it is doing clinical testing of DaunoXome in
 Germany, France, the United Kingdom, San Francisco and Los
 Angeles.

[This article is made available here by Dow Jones Co. for the
 personal and non-commercial use of callers to this bbs, in the
 hope that it will be of some help to those who are suffering
 from the disease and others who are seeking to help them.]